# Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

> **NCT00079066** · PHASE3 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 572 (actual)

## Conditions studied

- Colorectal Cancer
- Quality of Life

## Interventions

- **BIOLOGICAL:** cetuximab
- **PROCEDURE:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00079066
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12-30
- **Primary completion:** 2006-11-03
- **Final completion:** 2009-02-10
- **Target enrollment:** 572 (ACTUAL)
- **Last updated:** 2023-08-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00079066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00079066, "Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00079066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*